Results 21 to 30 of about 1,204,710 (358)

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2009
Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Donald A. Berry, Kristine Broglio
openaire   +3 more sources

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]

, 2016
Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F., Danesi, R., De Gregorio, V., Falcone, A., Fornaro, L., Graziano, F., Loupakis, F., Masi, G., Paolicchi, E., Ricci, V., Ronzoni, M., Vivaldi, C.   +11 more
core   +1 more source

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Progression‐free survival as a surrogate marker of overall survival [PDF]

Cancer, 2011
The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire   +3 more sources

Who Is In Charge, and Who Should Be? The Disciplinary Role of the Commander in Military Justice Systems [PDF]

, 2006
BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
Abrey, Lauren, Brandes, Alba A., Carpentier, Antoine F., Cernea, Dana, Chinot, Olivier L., Cloughesy, Timothy, Henriksson, Roger, Hilton, Magalie, Hoang-Xuan, Khe, Kavan, Petr, Mason, Warren, Nishikawa, Ryo, Saran, Frank, Wick, Wolfgang   +13 more
core   +3 more sources

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]

, 2016
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Miller, Kathy, Molnar, Istvan, Reynolds, Joseph G, Riahi, Kaveh, Tripathy, Debu, Verma, Sunil, Wickham, Thomas J, Yardley, Denise A   +10 more
core   +2 more sources

Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Cancer Treatment and Research Communications, 2021
Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj   +1 more source

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]

, 2008
Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Abrey LE, Barbara Poellinger, Ceresoli GR, Delattre Y, Horst Wagner, Hotta K, Joachim von Pawel, Khantia D, Lai CS, Namba Y, Regine WF, Rodrigus P, Thomas Duell, Zabel A   +13 more
core   +1 more source

Circulating cell death products predict clinical outcome of colorectal cancer patients. [PDF]

, 2009
BackgroundTumor cell death generates products that can be measured in the circulation of cancer patients. CK18-Asp396 (M30 antigen) is a caspase-degraded product of cytokeratin 18 (CK18), produced by apoptotic epithelial cells, and is elevated in breast ...
Hommes, Daan W, Koelink, Pim J, Lamers, Cornelis Bhw, Verspaget, Hein W   +3 more
core   +2 more sources

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer [PDF]

, 2016
BACKGROUND A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ...
Birrer, Michael J., Boente, Matthew P., Brady, Mark F., Chan, John K., Davidson, Susan A., DiSilvestro, Paul A., Huang, Helen, Huh, Warner K., Martin, Lainie P., Michael, Helen, Monk, Bradley J., O'Malley, David M., Penson, Richard T., Rubin, Stephen C., Walker, Joan L.   +14 more
core   +2 more sources